 Guardion Health Sciences, Inc. Guardion or the Company GHSI, a company that i develops medical foods and medical devices in the ocular health marketplace and ii is developing nutraceuticals that the Company believes will provide health benefits to consumers, announced today the publication of study data comparing the efficacy of the Companys micronized liquid formula Lumega-Z, to the current standard AREDS 2 soft gel supplement. Results from the study concluded that Guardions unique, proprietary formulation, Lumega-Z, provided significantly higher blood concentration levels of carotenoids, which have been shown by studies sponsored by the National Eye Institute to be important for slowing the progression of macular degeneration in certain patients, and the MPOD, which has been shown in studies to be an important and modifiable biomarker to track the progression of macular degeneration and other eye diseases. 